StreetInsider.com News Articles

Allergan Aesthetics Announces 2026 Grant Recipients of The Confidence Collective, Funded by BOTOX® Cosmetic (onabotulinumtoxinA)

Tue, 27 Oct 2026 08:30:00 -0400

Since its inception, The Confidence Collective has supported more than 500 women entrepreneurs and awarded more than $1.5 million in grants to fuel business growth and empower confidence.
In 2026 alone, BOTOX^® Cosmetic awarded 20 women entrepreneurs each with a $20,000 grant to help advance their business goals.

Allergan Aesthetics Announces 2026 Grant Recipients of The Confidence Collective, Funded by BOTOX® Cosmetic (onabotulinumtoxinA)

Tue, 27 Oct 2026 08:30:00 -0400

Since its inception, The Confidence Collective has supported more than 500 women entrepreneurs and awarded more than $1.5 million in grants to fuel business growth and empower confidence.
In 2026 alone, BOTOX^® Cosmetic awarded 20 women entrepreneurs each with a $20,000 grant to help advance their business goals.

AbbVie files FDA application for etentamig in relapsed multiple myeloma

Tue, 27 Oct 2026 08:00:21 -0400

AbbVie (NYSE: ABBV) has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration for etentamig, an investigational BCMA x CD3 bispecific antibody T-cell engager, for the treatment of adults with relapsed or refractory multiple myeloma.

The submission is based on results from the Phase 3 CERVINO study, which evaluated etentamig against investigator's choice of standard available therapies in 393 patients with triple-class exposed relapsed or refractory multiple myeloma who had received at least two prior lines of therapy.

In the trial, etentamig achieved a 74.0% overall response rate compared with 45.7% for standard therapies, along with a 60%

AbbVie Submits Biologics License Application (BLA) for Etentamig to U.S. FDA for Adults Living With Relapsed/Refractory Multiple Myeloma

Tue, 27 Oct 2026 08:00:00 -0400

– Etentamig is a second-generation BCMA-directed bispecific antibody T-cell engager with a clinical profile and dosing schedule that can potentially support treatment across a broad range of settings, including in community-based care
– In the Phase 3 CERVINO study, etentamig achieved statistically significant improvements in overall response rate (ORR) and progression-free survival (PFS) versus investigator's choice of standard available therapies
– Submission underscores AbbVie's ambition to advance a broad multiple myeloma portfolio that addresses disease complexity and supports patients' evolving care

AbbVie Submits Biologics License Application (BLA) for Etentamig to U.S. FDA for Adults Living With Relapsed/Refractory Multiple Myeloma

Tue, 27 Oct 2026 08:00:00 -0400

– Etentamig is a second-generation BCMA-directed bispecific antibody T-cell engager with a clinical profile and dosing schedule that can potentially support treatment across a broad range of settings, including in community-based care
– In the Phase 3 CERVINO study, etentamig achieved statistically significant improvements in overall response rate (ORR) and progression-free survival (PFS) versus investigator's choice of standard available therapies
– Submission underscores AbbVie's ambition to advance a broad multiple myeloma portfolio that addresses disease complexity and supports patients' evolving care

Avalo Therapeutics Inc. (AVTX) PT Lowered to $16 at Oppenheimer

Mon, 26 Oct 2026 13:53:47 -0400

Oppenheimer analyst Leland Gershell lowered the price target on Avalo Therapeutics Inc. (NASDAQ: AVTX) to $16.00 (from $35.00) while maintaining a Outperform rating.
The analyst comments "ABBV’s underwhelming Phase 3 HS results for lutikizumab, which shares IL-1β inhibition with abdakibart, appear to have heightened investor concern about AVTX’s lead asset ahead of its planned registrational trial. Luti (anti-IL1α/β) delivered an eight-percentage-point placebo-adjusted benefit on INTREPID’s Week 16 HiSCR75 primary endpoint—below the 21-point separation in its Phase 2 weekly arm and ~half that reported for UCB’s Bimzelx—with both lower active and higher placebo responses vs. Phase 2. However, population differences complicate the

Avalo Therapeutics Inc. (AVTX) PT Lowered to $16 at Oppenheimer

Mon, 26 Oct 2026 13:53:47 -0400

Oppenheimer analyst Leland Gershell lowered the price target on Avalo Therapeutics Inc. (NASDAQ: AVTX) to $16.00 (from $35.00) while maintaining a Outperform rating.
The analyst comments "ABBV’s underwhelming Phase 3 HS results for lutikizumab, which shares IL-1β inhibition with abdakibart, appear to have heightened investor concern about AVTX’s lead asset ahead of its planned registrational trial. Luti (anti-IL1α/β) delivered an eight-percentage-point placebo-adjusted benefit on INTREPID’s Week 16 HiSCR75 primary endpoint—below the 21-point separation in its Phase 2 weekly arm and ~half that reported for UCB’s Bimzelx—with both lower active and higher placebo responses vs. Phase 2. However, population differences complicate the

Avalo Therapeutics Inc. (AVTX) PT Lowered to $16 at Oppenheimer

Mon, 26 Oct 2026 13:53:47 -0400

Oppenheimer analyst Leland Gershell lowered the price target on Avalo Therapeutics Inc. (NASDAQ: AVTX) to $16.00 (from $35.00) while maintaining a Outperform rating.
The analyst comments "ABBV’s underwhelming Phase 3 HS results for lutikizumab, which shares IL-1β inhibition with abdakibart, appear to have heightened investor concern about AVTX’s lead asset ahead of its planned registrational trial. Luti (anti-IL1α/β) delivered an eight-percentage-point placebo-adjusted benefit on INTREPID’s Week 16 HiSCR75 primary endpoint—below the 21-point separation in its Phase 2 weekly arm and ~half that reported for UCB’s Bimzelx—with both lower active and higher placebo responses vs. Phase 2. However, population differences complicate the

Avalo Therapeutics Inc. (AVTX) PT Lowered to $16 at Oppenheimer

Mon, 26 Oct 2026 13:53:47 -0400

Oppenheimer analyst Leland Gershell lowered the price target on Avalo Therapeutics Inc. (NASDAQ: AVTX) to $16.00 (from $35.00) while maintaining a Outperform rating.
The analyst comments "ABBV’s underwhelming Phase 3 HS results for lutikizumab, which shares IL-1β inhibition with abdakibart, appear to have heightened investor concern about AVTX’s lead asset ahead of its planned registrational trial. Luti (anti-IL1α/β) delivered an eight-percentage-point placebo-adjusted benefit on INTREPID’s Week 16 HiSCR75 primary endpoint—below the 21-point separation in its Phase 2 weekly arm and ~half that reported for UCB’s Bimzelx—with both lower active and higher placebo responses vs. Phase 2. However, population differences complicate the

Allergan Aesthetics Celebrates Eight Years of Engaging Girls in STEM Through Continued Partnership with Girls Inc.

Mon, 26 Oct 2026 08:00:00 -0400

Allergan Aesthetics and Girls Inc. continue their commitment to expanding mentorship, education and career exploration opportunities for girls nationwide.

A STEM-focused workshop in San Antonio will bring together 20 Girls Inc. participants and alumnae for an educational experience

Allergan Aesthetics Celebrates Eight Years of Engaging Girls in STEM Through Continued Partnership with Girls Inc.

Mon, 26 Oct 2026 08:00:00 -0400

Allergan Aesthetics and Girls Inc. continue their commitment to expanding mentorship, education and career exploration opportunities for girls nationwide.

A STEM-focused workshop in San Antonio will bring together 20 Girls Inc. participants and alumnae for an educational experience

Form 3 AbbVie Inc. For: Oct 14 Filed by: Carethers John

Fri, 23 Oct 2026 17:05:00 -0400
si-local-file:///var/storage/secattach/20261023/27228569.html

FDA clears subcutaneous induction option for AbbVie's Skyrizi in Crohn's

Fri, 23 Oct 2026 15:34:18 -0400

The U.S. Food and Drug Administration has approved a subcutaneous induction regimen for AbbVie's (NYSE: ABBV) Skyrizi (risankizumab-rzaa) in adults with moderately to severely active Crohn's disease, allowing patients to begin treatment at home using an on-body injector (OBI) device.

The approval, based on results from the Phase 3 AFFIRM trial, adds a home-based induction option alongside the existing intravenous route. The subcutaneous induction dose is 720 mg delivered via OBI at weeks 0, 2, 4, and 8, followed by maintenance dosing every eight weeks. The intravenous option remains available at 600 mg at weeks 0, 4, and 8.

In the AFFIRM

U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease

Fri, 23 Oct 2026 15:33:00 -0400

Now with a new route of induction administration, subcutaneous SKYRIZI supports early symptomatic and endoscopic control with an on-body injector (OBI) device throughout the course of treatment

In the pivotal Phase 3 AFFIRM study, subcutaneous (SC) SKYRIZI^®achieved superior clinical remissionⁱ and endoscopic responseⁱⁱ at week 12

U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease

Fri, 23 Oct 2026 15:33:00 -0400

Now with a new route of induction administration, subcutaneous SKYRIZI supports early symptomatic and endoscopic control with an on-body injector (OBI) device throughout the course of treatment

In the pivotal Phase 3 AFFIRM study, subcutaneous (SC) SKYRIZI^®achieved superior clinical remissionⁱ and endoscopic responseⁱⁱ at week 12

Abbvie (ABBV) PT Raised to $294 at Goldman Sachs

Fri, 23 Oct 2026 06:51:40 -0400
Goldman Sachs analyst Asad Haider raised the price target on Abbvie (NYSE: ABBV) to $294.00 (from $258.00) while maintaining a Neutral rating.

AbbVie's lutikizumab meets primary endpoint in phase 3 HS trial

Thu, 22 Oct 2026 09:01:29 -0400

AbbVie (NYSE: ABBV) announced topline results from its Phase 3 INTREPID study showing that lutikizumab, an investigational dual IL-1α/1β antagonist, met its primary endpoint in adults and adolescents with moderate to severe hidradenitis suppurativa (HS).

In the randomized, double-blind, placebo-controlled trial of 1,400 patients, 31.4% of those treated with lutikizumab achieved the primary endpoint of HiSCR75 at Week 16, compared with 23.4% in the placebo group (p≤0.001). HiSCR75 is defined as at least a 75% reduction from baseline in total abscess and inflammatory nodule count, with no increase in abscess or draining fistula count.

The drug also met eight ranked secondary endpoints.

AbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis Suppurativa

Thu, 22 Oct 2026 09:00:00 -0400

In the Phase 3 INTREPID study, lutikizumab achieved the primary endpoint of Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16 compared with placebo¹

Lutikizumab met 8 ranked secondary endpoints, including significant improvements in HS-related skin pain at Week 8 and significant reductions in the occurrence of HS

AbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis Suppurativa

Thu, 22 Oct 2026 09:00:00 -0400

In the Phase 3 INTREPID study, lutikizumab achieved the primary endpoint of Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16 compared with placebo¹

Lutikizumab met 8 ranked secondary endpoints, including significant improvements in HS-related skin pain at Week 8 and significant reductions in the occurrence of HS

Allergan Aesthetics presents eight posters at AMWC Dubai

Wed, 21 Oct 2026 08:02:02 -0400

Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, is presenting eight scientific posters at the Aesthetic & Anti-Aging Medicine World Congress (AMWC) in Dubai, running October 21-23, 2026.
The presentations cover products including HArmonyCa™, Juvéderm®, Skinvive™ and Botox® Cosmetic. HArmonyCa™, which recently launched in the United Arab Emirates, is a hybrid facial injectable combining hyaluronic acid and calcium hydroxyapatite.
One poster presents a subgroup analysis of eight patients using GLP-1 weight-loss medications who were treated with HArmonyCa™. All eight participants showed visible midface improvement at three months, according to the press release. The findings are described as preliminary evidence for addressing facial volume

Allergan Aesthetics Deepens Science Behind Multimodal Approach at AMWC Dubai, Backed by Growing HArmonyCa™ Evidence

Wed, 21 Oct 2026 08:00:00 -0400

Allergan Aesthetics will present eight scientific posters featuring new and long-term evidence across HArmonyCa™, JUVÉDERM^®, SKINVIVE™ and BOTOX^® Cosmetic

The latest HArmonyCa™ data reinforces its dual-action technology, supported by long-term clinical efficacy data and new findings in patients undergoing medical weight loss

Allergan Aesthetics Deepens Science Behind Multimodal Approach at AMWC Dubai, Backed by Growing HArmonyCa™ Evidence

Wed, 21 Oct 2026 08:00:00 -0400

Allergan Aesthetics will present eight scientific posters featuring new and long-term evidence across HArmonyCa™, JUVÉDERM^®, SKINVIVE™ and BOTOX^® Cosmetic

The latest HArmonyCa™ data reinforces its dual-action technology, supported by long-term clinical efficacy data and new findings in patients undergoing medical weight loss

Abbvie (ABBV) PT Raised to $325 at Barclays

Wed, 21 Oct 2026 03:15:19 -0400
Barclays analyst Carter Gould raised the price target on Abbvie (NYSE: ABBV) to $325.00 (from $300.00) while maintaining a Overweight rating.

AbbVie Named Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 Team, Launches AbbVie Race to Innovate to Support Immunology Community

Tue, 20 Oct 2026 07:55:00 -0400

Multi-year, purpose-driven campaign connects McLaren's on-track performance with support for global patient advocacy organizations serving people living with immune-mediated diseases

Through the partnership, AbbVie will donate $10,000 to global charities for every 10 Constructors' Championship points earned by McLaren, reflecting approximately 10% of people worldwide

AbbVie Named Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 Team, Launches AbbVie Race to Innovate to Support Immunology Community

Tue, 20 Oct 2026 07:55:00 -0400

Multi-year, purpose-driven campaign connects McLaren's on-track performance with support for global patient advocacy organizations serving people living with immune-mediated diseases

Through the partnership, AbbVie will donate $10,000 to global charities for every 10 Constructors' Championship points earned by McLaren, reflecting approximately 10% of people worldwide